However, several groups have shown that pharmacological reduction of ghrelin to normal levels in PWS, using either short or long-acting somatostatin analogue (SSA), did not improve feeding behaviour and did not reduce the appetite of children and adults with PWS nor affect the weight [55, 112]. The gene discussed is GHRL; the disease is Prader-Willi syndrome.